{"url_path":"/sec/tsha/8-k/2026-06-02/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-253478-index.html","accession_number":"0001193125-26-253478","cik":"0001806310","ticker":"TSHA","issuer_name":"Taysha Gene Therapies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-253478-index.html","primary_entity_key":"0001806310","primary_entity_name":"Taysha Gene Therapies, Inc."},"word_count":473,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 1, 2026, Taysha Gene Therapies, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders considered four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2026 (the “Proxy Statement”). Of the 287,341,999 shares outstanding as of the record date, 243,857,812 shares, or approximately 84.86%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.\n\nProposal No. 1: Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:\n\n \n\nName\n  \nVotes For\n \n  \nVotes Withheld\n \n\nSean P. Nolan\n\n  \n \n169,142,295\n \n  \n \n35,742,331\n \n\nLaura Sepp-Lorenzino, Ph.D.\n\n  \n \n150,094,517\n \n  \n \n54,790,109\n \n\nBroker Non-Votes: 38,973,186\n\nBoth nominees were elected.\n\nProposal No. 2: Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:\n\n \n\n \n  \nVotes For\n \n  \nVotes Against\n \n  \nAbstained\n \n\nRatification of selection of Deloitte & Touche LLP\n\n  \n \n243,814,085\n \n  \n \n25,551\n \n  \n \n18,176\n \n\nBroker Non-Votes: 0\n\nProposal No. 3: Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows:\n\n \n\n \n  \nVotes For\n \n  \nVotes Against\n \n  \nAbstained\n \n\nApproval of the compensation of the Company’s named executive officers\n\n  \n \n168,142,551\n \n  \n \n36,396,784\n \n  \n \n345,291\n \n\nBroker Non-Votes: 38,973,186\n\nProposal No. 4: Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows:\n\n \n\n \n  \nOne Year\n \n  \nTwo\nYears\n \n  \nThree\nYears\n \n  \nAbstained\n \n\nAdvisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation\n\n  \n \n203,825,717\n \n  \n \n360,924\n \n  \n \n630,378\n \n  \n \n67,607\n \n\nBroker Non-Votes: 38,973,186\n\nConsistent with the stockholder voting results above and the recommendation of the board of directors of the Company (the “Board”) as disclosed in the Proxy Statement for the Annual Meeting, the Company has determined to solicit a non-binding advisory vote on the compensation of the Company’s named executive officers every year until the next required stockholder vote on the frequency of such non-binding advisory vote, or until the Board of the Company determines that a different frequency of such non-binding advisory vote is in the best interest of the Company’s stockholders.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nTaysha Gene Therapies, Inc.\n\nDated: June 2, 2026\n \n\n \nBy:\n \n\n/s/ Kamran Alam\n\n \n\n \n\n \nKamran Alam\n\n \n\n \n\n \nChief Financial Officer"}